SYD985 与多个主题相关，在 HER2 阳性转移性乳腺癌治疗中显示出积极结果，在联合免疫治疗和不同恶性肿瘤治疗方面具有潜力。此外，还有针对 Trop2、HER3、B7-H4 等靶点的 ADC 药物，如 Sacituzumab govitecan（SG）在 HER2 低表达乳腺癌治疗中也有潜力，但需明确 T-DXd 和 SG ...

HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

HER3 is expressed in more than 80% of EGFR-mutant ... Meanwhile, Daiichi Sankyo and AZ – its partner for approved HER2-targeting ADC Enhertu (trastuzumab deruxtecan) and investigational TROP2 ...

HER3 is expressed in more than 80% of EGFR-mutant ... Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third ...